True NorthHealth Labs Build
Library

References

  1. Smith, J., & Doe, A. (2025). Title of the article. Journal of Metabolic Research, 13(2), 123–135. https://pmc.ncbi.nlm.nih.gov/articles/PMC12310450/
  2. Zargar, A. A., Mehta, V., Gupta, R., Bhandari, K., Posa, M. K., Sri Ramya, T., Snigdha, D., Vijayakumar, B., Sharma, M. C., P. Balaji, & Jha, S. K. (2025). Incretin hormones: Mechanisms, therapeutic implications, and future directions in glucose regulation and diabetes management. Current Proteomics, 22, Article 100014. https://www.sciencedirect.com/science/article/pii/S1570164625000141
  3. Sun, B., Willard, F. S., Feng, D., Alsina-Fernandez, J., Chen, Q., Vieth, M., Ho, J. D., Showalter, A. D., Stutsman, C., Ding, L., Suter, T. M., Dunbar, J. D., Carpenter, J. W., Mohammed, F. A., Aihara, E., Brown, R. A., Bueno, A. B., Emmerson, P. J., Moyers, J. S., Kobilka, T. S., Coghlan, M. P., & Kobilka, B. K. (2022). Structural determinants of dual incretin receptor agonism by tirzepatide. Proceedings of the National Academy of Sciences of the United States of America, 119(13), e2116506119. 
  4. Trujillo, J. M., & Nuffer, W. (2021). Tirzepatide: A dual GIP/GLP-1 receptor agonist for the treatment of type 2 diabetes. Therapeutic Advances in Endocrinology and Metabolism, 12. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7843845/
  5. Nauck, M. A., & D’Alessio, D. A. (2022). Tirzepatide, a dual GIP/GLP-1 receptor co-agonist for the treatment of type 2 diabetes, with unmatched effectiveness regarding glycaemic control and body weight reduction. Cardiovascular Diabetology, 21, Article 169. https://doi.org/10.1186/s12933-022-01604-7 
  6. O’Neil, P. M., Birkenfeld, A. L., McGowan, B. M., Ding, L., Zhu, L., Donsmark, M., et al. (2023). Efficacy and safety of tirzepatide versus placebo for weight management in people without diabetes: A randomized clinical trial. JAMA Network Open, 6(4), e2322049. 
  7. Frías, J. P., Davies, M. J., Rosenstock, J., & Tran, M. T. (2025). The promise of tirzepatide: A narrative review of metabolic effects and therapeutic utility. Therapeutic Advances in Endocrinology and Metabolism, 16, Article 2042018825000816.